Back to Search
JAMES DOROSHOW, M.D.
M.D.
Medical Oncology Physician
NPI: 1255456174Individual
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
37308(MA)
Research & Publications (20)
Five strategies for accelerating the war on cancer in an era of budget deficits.
PMID 19147688·Oncologist·2009
8-other
Oncologic phase 0 trials incorporating clinical pharmacodynamics: from concept to patient.
PMID 18559579·Clin Cancer Res·2008
8-other
Commentary: publishing cancer clinical trial results: a scientific and ethical imperative.
PMID 18794215·Oncologist·2008
8-other
The role of the National Cancer Institute in drug development.
PMID 16166997·Clin Adv Hematol Oncol·2005
8-other
Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer.
PMID 19307510·J Clin Oncol·2009
3-trial
Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity.
PMID 19584232·Mol Cancer Ther·2009
4-observational
Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.
PMID 19364967·J Clin Oncol·2009
3-trial
Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies.
PMID 19091546·Eur J Cancer·2009
6-review
Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study.
PMID 19322566·Cancer Chemother Pharmacol·2009
3-trial
Expression of NADPH oxidase homologues and accessory genes in human cancer cell lines, tumours and adjacent normal tissues.
PMID 19431059·Free Radic Res·2009
8-other
A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study.
PMID 18981013·Clin Cancer Res·2008
3-trial
Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU).
PMID 17899082·Cancer Chemother Pharmacol·2008
3-trial
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.
PMID 18235115·J Clin Oncol·2008
3-trial
Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts.
PMID 18980982·Clin Cancer Res·2008
7-preclinical
Molecular profiling including epidermal growth factor receptor and p21 expression in high-risk breast cancer patients as indicators of outcome.
PMID 18641005·Ann Oncol·2008
8-other
Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies.
PMID 17875771·Clin Cancer Res·2007
3-trial
Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function.
PMID 17699862·Clin Cancer Res·2007
8-other
Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
PMID 18199854·Mol Interv·2007
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 3A44 BIDG 31, 31 CENTER DRIVE
BETHESDA, MD 20892 - Phone
- (301) 496-4291
Quick Facts
- NPI
- 1255456174
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile